We are pleased to share that all subjects in the prophylactic arm of the Phase 2a/b PROTECT clinical trial have received their initial dose of ISLA-101. They will be administered an attenuated strain of dengue fever on 4 October 2024, and we are just weeks away from understanding the potential impact of our drug ISLA-101 on dengue fever.